DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clinical Evaluation of a New Form of Cancer Therapy Based on the Principles of Atavistic Metamorphosis

Information source: Dr. Frank Arguello Cancer Clinic
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Neoplasms

Intervention: Anti-Bacterial Agents (Drug); Anti-Fungal Agents (Drug); Anti-Protozoal Agents (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Dr. Frank Arguello Cancer Clinic

Official(s) and/or principal investigator(s):
Frank Arguello, MD, Principal Investigator, Affiliation: Dr. Frank Arguello Cancer Clinic
Rafael Argüello-Astorga, MD, PhD, Principal Investigator, Affiliation: Instituto de Ciencia y Medicina Genomica


The cell behavior that the investigators regard as "malignant," including: cell autonomy; invasion and digestion of surrounding normal tissues; migration and colonization of distant organs; ability to develop resistance to drugs, temperature, or radiation; and ability to kill the host, are not only characteristics of cancer cells, but of pathogenic and/or opportunistic unicellular organisms (bacteria, fungi and protozoa). Rudolf Virchow (1821-1902), the father of modern pathology, first pointed out the resemblance between the biological behavior of cancer cells and that of single-celled organisms when causing infections. He thought, incorrectly, that cancer cells were cells infected with bacteria and had acquired their pathogenic behavior from them. Others later postulated that the behavior of cancer cells was likely due to the re-expression of past traits and behaviors (atavism) derived from their past evolutionary experience as independent, single-celled organisms from which all cells in multicellular organisms originated. In other words, the behavior of pathogenic unicellular organisms, including: unlimited replicative potential; capacity for invasion, migration, and metastases; abilities to evade the host's immune system, to generate multi-drug resistance; and to kill a host, are what the investigators define as "cancer" when one of the investigators cells re-express these past ancestral traits. This reversion or de-evolution of a differentiated cell to its ancestral undifferentiated, unicellular form has been named "Atavistic Metamorphosis." This does not imply that cancer cells are bacteria, protozoa, or yeasts. It means that cancer cells express functions and/or behaviors similar to their ancestral parents, the unicellular organisms from which our cells originated. If this is true, a combination of drugs that are effective to eradicate certain unicellular organisms may work in cancer treatment. The principal objective of this study is to determine whether there is a benefit for patients with advanced, metastatic and terminal cancers to be treated with combinations of selected drugs conventionally used in medical practice to kill bacterial, fungal and protozoal cells.

Clinical Details

Official title: Atavistic Chemotherapy and Immunotherapy in Advanced, Metastatic, and Otherwise Incurable and Lethal Cancers Under Conventional Treatments

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Clinical efficacy as measured by the number of participants with an objective clinical tumor regression response

Secondary outcome:

Clinical efficacy as measured by the number of participants with an objective clinical tumor regression response

Clinical safety as measured by the incidence of adverse events in each intervention group

Detailed description: This is an investigator initiated, randomized, single-blind, response-adaptive trial conducted at two sites in patients who have tried conventional therapy and failed or have refused conventional therapy. This study is being conducted to determine the efficacy of combinations of marketed drugs against unicellular organisms in cancer treatment. The products under investigation include FDA- and SSA-approved anti-bacterial, anti-fungal and anti-protozoan drugs with documented anti-cancer properties. The drugs under study are compatible with each other, and used at pharmacological dosages known to be tolerable and safe in humans and/or cancer patients with limited adverse effects. Patients receive treatment for 10 to 12 months. The duration of treatment is depended on the drugs investigated. It is hypothesized that regression will occur within 6 months and treatment will be continued with the assumption that this may prevent recurrences. Outcomes will be measured objectively and assessments appropriate for the type of cancer treated. Outcome measures may include 1) Changes in signs and symptoms; (2) Visual inspection of tumors using weekly photographs and measurements (as appropriate); (3)Monthly chest X-rays to monitor lung tumors, lung metastases and/or fluid in the chest; (4) Ultrasound to evaluate abdominal tumors (e. g., liver metastases), and breast and armpit lymph nodes; (5) CT, MRI and PET scans; (6) Tumor markers in blood such as Carcinoembryonic Antigen (CEA), CA-15. 3, CA-19-9, etc. and other laboratory studies to monitor response. The overall goal of this study is to understand the efficacy of atavistic chemotherapy that may mediate metastatic or terminal cancer regression or cure.


Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria:

- Patients with malignant disease confirmed histologically that is considered

untreatable, progressive and fatal within the next 16 months.

- Patient with an expectation of life greater than 3 months.

- Patients with malignant disease that may be evaluated or measured clinically either

through radiographic studies, visually, histologically, in serum or blood tumor markers, or through any other method medical approved for that disease. Exclusion Criteria:

- Patients over 75 years of age.

- Patients who are pregnant.

- Patients that have a known allergy to any of the drugs planned for use.

- Patients with renal, hepatic, pulmonary, cardiovascular compromise, or other systemic

or other clinical conditions such as AIDS, tuberculosis, etc., which, in the opinion of the Investigator, may pose a risk to the subject.

- Malignancies of hemato-lymphatic origin (leukemias and lymphomas)

Locations and Contacts

Dr. Frank Arguello Cancer Clinic, San Jose del Cabo, Baja California Sur, Mexico; Recruiting
Frank Arguello, MD, Phone: 624 174 9260
Frank Arguello, MD, Principal Investigator

Instituto de Ciencia y Medicina Genomica, Torreon, Coahuila, Mexico; Recruiting
Rafael Argüello-Astorga, MD, PhD, Phone: 871 747 0500
Rafael Argüello-Astorga, MD, PhD, Principal Investigator

Additional Information

Starting date: July 2011
Last updated: August 18, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017